Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 08/31
| 02-2025 | 11-2024 | 08-2024 | 05-2024 | 02-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,469 | 8,078 | 6,500 | 8,459 | 4,705 |
| Marketable Securities | 74 | 40 | 56 | 46 | 88 |
| Receivables | 331 | 264 | 155 | 208 | 357 |
| TOTAL | $7,724 | $8,826 | $7,898 | $9,093 | $5,417 |
| Non-Current Assets | |||||
| PPE Net | 262 | 271 | 255 | 219 | 226 |
| Intangibles | 506 | 505 | 517 | 499 | 519 |
| Other Non-Current Assets | 185 | 192 | 198 | 207 | 190 |
| TOTAL | $953 | $968 | $970 | $925 | $935 |
| Total Assets | $8,678 | $9,794 | $8,868 | $10,018 | $6,352 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,793 | 269 | 1,066 | 129 | 55 |
| TOTAL | $1,822 | $298 | $1,099 | $156 | $82 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 0 | 0 | 5 | N/A | N/A |
| Other Non-Current Liabilities | 98 | 105 | 111 | 118 | 126 |
| TOTAL | $94 | $102 | $109 | $115 | $123 |
| Total Liabilities | $1,917 | $400 | $1,209 | $271 | $204 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,559 | 17,553 | 17,453 | 15,810 | 12,886 |
| Common Shares | 18 | 18 | 16 | 16 | 12 |
| Retained earnings | -56,976 | -54,263 | -51,559 | -49,374 | -47,592 |
| Other shareholders' equity | -502 | -403 | -397 | -397 | -394 |
| TOTAL | $6,761 | $9,394 | $7,659 | $9,747 | $6,148 |
| Total Liabilities And Equity | $8,678 | $9,794 | $8,868 | $10,019 | $6,352 |